Overview

Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Status:
Recruiting

Trial end date:
2020-09-01

Target enrollment:

Participant gender:

Summary

It is clear now that SARS-CoV-2 could use angiotensin-converting enzyme 2 (ACE2), the same receptor as SARS-CoV Transmembrane protease serine type 2 (TMPRSS2), a protease belonging to the type II transmembrane serine protease family, cleaves the coronavirus spike protein Serine proteases are inhibited by a diverse group of inhibitors, The best-studied serpins are antithrombin and alpha 1-antitrypsin

Phase:

Early Phase 1

Details

Lead Sponsor:

Ministry of Health, Saudi Arabia

Treatments:

Alpha 1-Antitrypsin
Protein C Inhibitor